Therapeutic uses of furin and its inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 4, 2015, Pages 379-396

  Couture, Frédéric ^a   Kwiatkowska, Anna ^a   Dory, Yves L ^a   Day, Robert ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Furin; Peptide and peptidomimetic inhibitors; Proprotein convertase; 1 antitrypsin Portland

Indexed keywords

BACTERIAL PROTEIN; CANCER VACCINE; CIPROFLOXACIN; FURIN; PEPTIDE; PEPTIDOMIMETIC AGENT; TRYPSIN INHIBITOR; VIRUS PROTEIN;

AMINO ACID SEQUENCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN DEGRADATION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; GENE SILENCING; METABOLISM; PATENT;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FURIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; PATENTS AS TOPIC; PEPTIDOMIMETICS;

EID: 84924978499     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.1000303     Document Type: Review

References (95)

1. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11(5):367-83
2. Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med 2011;365(26):2507-18
3. Wan L, Molloy SS, Thomas L, et al. PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell 1998;94(2):205-16
4. Dittie AS, Thomas L, Thomas G, et al. Interaction of furin in immature secretory granules from neuroendocrine cells with the AP-1 adaptor complex is modulated by casein kinase II phosphorylation. EMBO J 1997;16(16):4859-70
5. Roebroek AJ, Umans L, Pauli IG, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 1998;125(24):4863-76
6. Malfait AM, Seymour AB, Gao F, et al. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis 2012;71(6):1042-8
7. Scamuffa N, Calvo F, Chrétien M, et al. Proprotein convertases: lessons from knockouts. FASEB J 2006;20:1954-63
8. Creemers JW, Khatib AM. Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front Biosci 2008;172:4960-71
9. Roebroek AJ, Taylor NA, Louagie E, et al. Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 2004;279(51):53442-50
10. Couture F, D'Anjou F, Day R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts 2011;2(5):421-38
11. Taylor NA, Van De Ven WJ, Creemers JW. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 2003;17(10):1215-27
12. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002;3(10):753-66
13. Khatib A-M, Siegfried G, Chrétien M, et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002;160:1921-35
14. Harris NC, Achen MG. The proteolytic activation of angiogenic and lymphangiogenic growth factors in cancer - its potential relevance for therapeutics and diagnostics. Curr Med Chem 2013. [Epub ahead of print]
15. Bassi DE, Fu J, Lopez de Cicco R, et al. Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol Carcinog 2005;44(3):151-61
16. Mbikay M, Sirois F, Yao J, et al. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75(10):1509-14
17. Cheng M, Watson PH, Paterson JA, et al. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71(6):966-71
18. Bassi DE, Mahloogi H, Al-Saleem L, et al. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001;31(4):224-32
19. D'Anjou F, Routhier S, Perreault JP, et al. Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 2011;4(3):157-72
20. McColl BK, Paavonen K, Karnezis T, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 2007;21(4):1088-98
21. Harris NC, Paavonen K, Davydova N, et al. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J 2011;25(8):2615-25
22. Bassi DE, Mahloogi H, Lopez De Cicco R, et al. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003;162(2):439-47
23. Page RE, Klein-Szanto AJP, Litwin S, et al. Increased expression of the proprotein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 2007;29:289-99
24. Lin H, Ah Kioon MD, Lalou C, et al. Protective role of systemic furin in immune response-induced arthritis. Arthritis Rheum 2012;64(9):2878-86
25. Dubois CM, Blanchette F, Laprise MH, et al. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 2001;158(1):305-16
26. Sanjabi S, Zenewicz LA, Kamanaka M, et al. Anti-inflammatory and proinflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009;9(4):447-53
27. de Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 1999;13(8):1188-99
28. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18(7):816-27
29. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52(1):128-35
30. Pesu M, Watford WT, Wei L, et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008;455(7210):246-50
31. Hallenberger S, Bosch V, Angliker H, et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992;360(6402):358-61
32. Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999;44(Suppl B):3-9
33. Fugère M, Day R. Cutting back on proprotein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 2005;26(6):294-301
34. Anderson S, Laskowski M. inventors Novel protein inhibitors of serine proteinases (e.g., furin) derived from turkey ovomucoid third domain patent. WO002055; 1995
35. Lu W, Zhang W, Molloy SS, et al. Arg15-Lys17-Arg18 turkey ovomucoid third domain inhibits human furin. J Biol Chem 1993;268(20):14583-5
36. Anderson ED, Thomas L, Hayflick JS, et al. Inhibition of HIV-1 gp160-dependent membrane fusion by a furindirected alpha 1-antitrypsin variant. J Biol Chem 1993;268(33):24887-91
37. Jean F, Stella K, Thomas L, et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 1998;95(13):7293-8
38. Thomas G, Anderson ED, Thomas L, et al. inventors Methods and reagents for inhibiting furin endoprotease patent. WO016073; 1994
39. Jean F, Thomas G. inventors Reagents and methods for inhibiting furin protease activity patent. WO051624; 1999
40. Basak A, Lotfipour F. Modulating furin activity with designed mini-PDX peptides: synthesis and in vitro kinetic evaluation. FEBS Lett 2005;579(21):4813-21
41. Dufour EK, Denault JB, Hopkins PC, et al. Serpin-like properties of alpha1-antitrypsin Portland towards furin convertase. FEBS Lett 1998;426(1):41-6
42. Dubois C. inventor Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases patent. US0127396; 2004
43. Cohen-Solal M, Khatib A-M. inventors Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease patent. WO144517; 2011
44. Wahl SM, Allen JB, Costa GL, et al. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med 1993;177(1):225-30
45. Brandes ME, Allen JB, Ogawa Y, et al. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991;87(3):1108-13
46. Matsuda S, Matsuda Y, D'Adamio L. BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2. J Biol Chem 2009;284(23):15815-25
47. D'Adamio L, Shuji M. inventors Effect of bri proteins on abeta production patent. WO138355; 2006
48. Cameron A, Appel J, Houghten RA, et al. Polyarginines are potent furin inhibitors. J Biol Chem 2000;275(47):36741-9
49. Kacprzak MM, Peinado JR, Than ME, et al. Inhibition of furin by polyargininecontaining peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem 2004;279(35):36788-94
50. Lindberg I, Cameron A, Appel J, et al inventors Inhibiting furin with polybasic peptides patent. US0087827; 2003
51. Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002;70(12):7136-9
52. Sarac MS, Peinado JR, Leppla SH, et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect Immun 2004;72(1):602-5
53. Kibler KV, Miyazato A, Yedavalli VS, et al. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J Biol Chem 2004;279(47):49055-63
54. Karicherla P, Hobden JA. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2009;50(1):256-62
55. Karicherla P, Hobden JA. Nona-D-arginine amide for prophylaxis and treatment of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 2010;35(3):220-4
56. Karicherla P, Aras S, Aiyar A, et al. Nona-D-arginine amide suppresses corneal cytokines in Pseudomonas aeruginosa keratitis. Cornea 2010;29(11):1308-14
57. Day R, Lebl M, Strongin A. inventors Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens patent. WO023306; 2009
58. Monnier PP, Tassew NG. inventors Methods for promoting neuron survival, axonal growth and/or regeneration patent. WO3113107; 2013
59. Tassew NG, Charish J, Seidah NG, et al. SKI-1 and Furin generate multiple RGMa fragments that regulate axonal growth. Dev Cell 2012;22(2):391-402
60. Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992;11(7):2407-14
61. Garten W, Hallenberger S, Ortmann D, et al. Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie 1994;76(3-4):217-25
62. Henrich S, Cameron A, Bourenkov GP, et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003;10(7):520-6
63. Henrich S, Lindberg I, Bode W, et al. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 2005;345(2):211-27
64. Remacle AG, Gawlik K, Golubkov VS, et al. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 2010;42(6):987-95
65. Becker GL, Lu Y, Hardes K, et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 2012;287(26):21992-2003
66. Day PM, Richards R, Buck C, et al. inventors Furin inhibitors and alphadefensins for the treatment or prevention of papillomavirus infection patent. WO084131; 2006
67. Burd EM. Human papillomavirus and cervical cancer. Clinical microbiology reviews 2003;16(1):1-17
68. Bassi DE, Zhang J, Cenna J, et al. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia 2010;12(7):516-26
69. Kines RC, Thompson CD, Lowy DR, et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci USA 2009. 106(48):20458-63
70. Ferguson MW, Brunner G. inventors Use of furin "convertase" inhibitors in the treatment of fibrosis and scarring patent. WO009113; 2004
71. McColl B, Stacker S, Achen M. inventors Method for inhibiting angiogenesis and/or lymphangiogenesis patent. WO112971; 2005
72. Smith RE. inventor Furin inhibitors patent. WO046781; 2007
73. Steinmetzer T, Becker G, Garten W. inventors N-terminally modified tetrapeptide derivatives having a Cterminal arginine mimetic patent. WO048941; 2010
74. Kwiatkowska A, Couture F, Levesque C, et al. Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem 2014;57(1):98-109
75. Becker GL, Sielaff F, Than ME, et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010;53(3):1067-75
76. Dahms SO, Hardes K, Becker GL, et al. X-ray structures of human furin in complex with competitive inhibitors. ACS Chem Biol 2014;9(5):1113-18
77. Day R, Neugebauer WA, Dory YL. inventors Stable peptide-based furin inhibitors patent. WO029182; 2013
78. Gagnon H, Beauchemin S, Kwiatkowska A, et al. Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J Med Chem 2014;57(1):29-41
79. Strongin A, Pellecchia M, Barile E. inventors Inhibitors of furin and other pro-protein convertases patent. WO138666; 2013
80. Nemunaitis JJ, Senzer N, Maples PB, et al. inventors Furin-knockdown and gm-csf-augmented (fang) cancer vaccine patent. WO079077; 2011
81. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2001;10(50):52-60
82. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6(7):506-20
83. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136(10):3916-20
84. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8(5):369-80
85. Senzer N, Barve M, Kuhn J, et al. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 2012;20(3):679-86
86. Senzer N, Barve M, Nemunaitis J, et al. Long term follow up: phase i trial of "bishRNA furin/GMCSF DNA/autologous tumor cell" immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin 2013;4:209
87. Binley JM, Sanders RW, Master A, et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002;76(6):2606-16
88. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Partial maturation: an immune-evasion strategy of dengue virus? Trends Microbiol 2011;19(5):248-54
89. Neumann G, Feldmann H, Watanabe S, et al. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002;76(1):406-10
90. Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004;43(9):2438-44
91. Garten W, Stieneke A, Shaw E, et al. Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones. Virology 1989;172(1):25-31
92. Craik DJ, Fairlie DP, Liras S, et al. The future of peptide-based drugs. Chem Biol Drug Des 2013;81(1):136-47
93. Watanabe M, Hirano A, Stenglein S, et al. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J Virol 1995;69(5):3206-10
94. Levesque C, Fugere M, Kwiatkowska A, et al. The Multi-leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 2012;55(23):10501-
95. Fugere M, Limperis PC, Beaulieu-Audy V, et al. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 2002;277(10):7648-56